X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OPL-0401 is an investigational small molecule Rho kinase (ROCK) 1/2 inhibitor and a potential first-in-class oral option which is being evaluated for the treatment of patients with diabetic retinopathy.
Lead Product(s): OPL-0401
Therapeutic Area: Ophthalmology Product Name: OPL-0401
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
The collaboration will leverage Valo’s Opal Computational Platform including access to real-world patient data, AI-enabled small molecule discovery and Biowire® human tissue modelling platform to discover and develop novel treatments for cardiometabolic diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $2,760.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 25, 2023
Details:
OPL-0401 is an investigational small molecule Rho kinase (ROCK) 1⁄2 inhibitor and a potential first-in-class oral option for patients with NPDR, where the current treatment options are intravitreal injections, surgery, or laser treatment.
Lead Product(s): OPL-0401
Therapeutic Area: Ophthalmology Product Name: OPL-0401
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
